Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit improved therapeutic index and efficacy. Its FateControl technology increases ADC internalization in targeted tissues while reducing payload release in non-target tissues, aiming to improve performance independent of linker and payload. The company's lead program targets lung cancer and the firm plans to expand ADC use across additional indications and patient profiles. Proceeds from the announced financing will finance the lead program through first-in-human clinical studies and support pipeline development. Mythic positions its approach as a new dimension of ADC technology focused on manipulating ADC fate within the cell. Leadership includes co-founders Alex Nichols (President and CEO) and Brian Fiske (Chief Scientific Officer); the company is based in Waltham, Massachusetts.

Total raised

$103M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2021